P04.42
Newborn affected by maternal use of hallucinogens
Clinical Classification Guidelines
Excludes Type 2
- newborn affected by other maternal medication (P04.1-)
Medical Intelligence & Overview
ICD-10 code P04.42 refers to newborns affected by maternal use of hallucinogens during pregnancy. This condition can lead to various health concerns for the infant, both immediately after birth and potentially long-term. It is important to understand the causes, symptoms, diagnosis, and potential management of this condition to ensure appropriate care and support for affected newborns.
Causes & Symptoms
Clinical Causes: Maternal consumption of hallucinogenic substances such as LSD, peyote, psilocybin mushrooms, or other similar drugs during pregnancy. Use of substances that alter perception, mood, or consciousness by the mother while pregnant.
Key Symptoms: Altered neurological development in the newborn. Respiratory distress or breathing irregularities. Poor muscle tone or hypotonia. Feeding difficulties or poor weight gain. Irritability, jitteriness, or tremors. Sleep disturbances. Potential congenital anomalies if associated with other substance use.
Diagnostic & Treatment
Diagnosis Path: - Monitoring the infant’s neurological and behavioral responses over time.
Treatment Protocols: Monitoring vital signs and respiratory function. Providing a calm and soothing environment to minimize irritability and sleep disturbances. Assistance with feeding, including possibly use of specialized feeding techniques if needed. Supportive care for withdrawal symptoms if present. Referral to developmental specialists for ongoing assessment and intervention. Ensuring maternal support and counseling for substance use issues.
Clinical Advice & FAQs
Billing Guidance
Is P04.42 a billable ICD-10 code?
Yes, P04.42 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report P04.42?
Clinical documentation must specify the nature of Newborn affected by maternal use of hallucinogens and any associated comorbidities for accurate reporting.
Cite this Clinical Reference